Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, open-label, single-arm, multicenter, multinational study to evaluate the antitumor activity and safety of IPI-504 [retaspimycin], a novel small molecule inhibitor of heat shock protein 90(HSP90), in patients with locally advanced or metastatic human epidermal growth factor receptor 2 positive(HER2+) breast cancer that has progressed despite prior Her2-targeted therapy.

Next Previous
Search
Trial Profile

A phase 2, open-label, single-arm, multicenter, multinational study to evaluate the antitumor activity and safety of IPI-504 [retaspimycin], a novel small molecule inhibitor of heat shock protein 90(HSP90), in patients with locally advanced or metastatic human epidermal growth factor receptor 2 positive(HER2+) breast cancer that has progressed despite prior Her2-targeted therapy.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors MedImmune

    • Most Recent Events

    • 05 Feb 2010 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.
    • 20 Mar 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top